



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Oral intake of *Kluyveromyces marxianus* B0399 plus *Lactobacillus rhamnosus* CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial

Vicente Navarro-López^{a,b,*}, Adriana Hernández-Belmonte^b, Maria Isabel Pérez Soto^c, Maikel Ayo-González^d, Guillermo Losa-Rodríguez^d, Esther Ros-Sánchez^d, Maravillas Martínez-Gabarrón^d, Pedro Sánchez-Pellicer^a, Juan Aguera-Santos^a, Eva Núñez-Delegido^a, Beatriz Ruzafa-Costas^a, José Antonio Picó-Monllor^e, Laura Navarro-Moratalla^a

^a MiBioPath Research Group, Health and Science Faculty, Catholic University of Murcia, Campus de Los Jerónimos N 135, 30107, Murcia, Spain

^b Clinical Microbiology and Infectious Disease Unit, Hospital Universitario Del Vinalopó, 03293, Elche, Spain

^c Department of Internal Medicine, Hospital Universitario Del Vinalopó, 03293, Elche, Spain

^d Department of Hospital Homecare Unit, Hospital Universitario Del Vinalopó, 03293, Elche, Spain

^e Department of Pharmacology, Pediatrics and Organic Chemistry, Faculty of Pharmacy, Universidad Miguel Hernández de Elche, 03202, Elche, Spain

ARTICLE INFO

Keywords:
 COVID-19
 SARS-CoV-2
 Probiotics
 Microbiota
 Microbiome

ABSTRACT

At the beginning of the SARS-CoV-2 pandemic, developing of new treatments to control the spread of infection and decrease morbidity and mortality are necessary. This prospective, open-label, case-control intervention study evaluates the impact of the oral intake of the probiotic yeast *Kluyveromyces marxianus* B0399 together with *Lactobacillus rhamnosus* CECT 30579, administered for 30 days, on the evolution of COVID-19 patients. Analysis of the digestive symptoms at the end of the follow up shows a benefit of the probiotic in the number of patients without pyrosis (100% vs 33.3%; p 0.05) and without abdominal pain (100% vs 62.5%; p 0.04). Results also show a better evolution when evaluating the difference in the overall number of patients without non-digestive symptoms at the end of the follow-up (41.7%, vs 13%; p 0.06). The percentage of improvement in the digestive symptoms (65% vs 88%; p value 0.06) and the global symptoms (digestive and non-digestive) (88.6% vs 70.8%; p value 0.03) is higher in the probiotic group. The probiotic was well tolerated with no relevant side effects and high adherence among patients. In conclusion, this coadjuvant treatment seems to be promising, although results should be confirmed in new studies with higher number of patients.

1. Introduction

The SARS-CoV-2 coronavirus, the causal agent of the coronavirus disease 2019 (COVID-19), is an RNA virus belonging to the Coronaviridae family. Starting 2020, COVID-19 has been responsible for the worst pandemic suffered by humanity in the twenty-first century. Main COVID-19 transmission mechanisms demonstrated so far are airway through

Flügge droplets and contact transmission through the hands or recently contaminated objects [1]. Besides, SARS-CoV-2 can also be isolated as viable viral particles in stool samples from infected patients [2]. The intestinal epithelial cells, especially those enterocytes, express angiotensin converting enzyme-2 (ACE-2) receptors, as occurs with lung cells. These receptors play a crucial role in the pathogenesis of COVID-19, due to the capability of the virus to replicate in these cells [3], being

Abbreviations: COVID-19, coronavirus disease; RNA, ribonucleic acid; ACE-2, angiotensin converting enzyme-2; CECT, spanish type culture collection; CFU, colony-forming unit; CURB-65, pneumoniae severity score; ICU, intensive care unit; SPSS, Statistical Package for Social Science; HT, HT:Hypertension; COPD, chronic obstructive pulmonary disease; PCR, polymerase chain reaction; SD, standard deviation; HHU, home hospitalization unit; DVT, deep vein thrombosis; IBS, Intestine Bowel Syndrome.

* Corresponding author. MiBioPath Research Group, Health and Science Faculty, Catholic University of Murcia, Campus de Los Jerónimos N 135, 30107, Murcia, Spain.

E-mail addresses: vnavarro@ucam.edu, vicente.navarro@bioithas.com (V. Navarro-López).

<https://doi.org/10.1016/j.medmic.2022.100061>

Received 26 May 2022; Received in revised form 8 August 2022; Accepted 18 August 2022

Available online 24 August 2022

2590-0978/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

responsible for the respiratory and digestive symptoms that appear in COVID-19. A recent study showed that RNA was consistently detected in rectal swabs even after viral clearance from the upper respiratory tract, indicating extended duration of viral shedding in faecal samples and raising the possibility of fecal–oral transmission of SARS-CoV-2 [4].

The effect of viral infections on the gut microbiota has been described and the role of the gut microbiota influencing lung diseases has been well articulated [5]. Gut microbiota diversity is diminished in elderly people, and COVID-19 is especially cruel in these aged people. Several recent publications demonstrate that SARS-CoV-2 infection causes a significant alteration of the intestinal microbiota along with a decrease in biodiversity [6–8]. It is known that lower microbial biodiversity is a risk factor for bacterial translocation phenomena and consequently, a worsening of the patient's prognosis and symptoms, including systemic, respiratory, and digestive ones [9–11]. These facts highlight the idea of the gut microbiota impact on COVID-19 evolution and prognosis. Considering that many of the COVID-19 symptoms could be caused by intestinal dysbiosis, the hypothesis of acting on it by means of an intervention is raised, with the aim of changing the natural development of the infection and thus, turning the coronavirus presence in faecal samples negative faster. In fact, a phenotype of patients with a greater presence of digestive symptoms has been described and hypothesized that this COVID-19 phenotype could be related to a greater presence of ACE receptors in their intestinal mucosa [12–15]. Consequently, it is reasonable to propose treatments aimed at modulating the gut microbiota to improve prognosis and reduce the symptoms. Considering their already demonstrated beneficial effects in various digestive pathologies, probiotics seem to be a feasible option among other treatments [16–19]. In fact, recently a few publications studied the effect of different probiotic strains in COVID-19 patients, with promising results [20–22].

We proposed this study to validate the effectiveness of a specific probiotic formulation of a yeast and a lactobacillus in symptomatic COVID-19 patients with moderate involvement, especially in digestive symptoms. The mixture of probiotics used was selected based in previous clinical and preclinical studies. *Lactobacillus rhamnosus* CECT 30579 strain was tested in vitro together with other *L. rhamnosus* strains and selected based on internal unpublished data. *Kluyveromyces marxianus* B0399 has been studied in different clinical trials where it has shown to be effective in controlling digestive symptoms in some intestinal diseases, including diarrhea associated to the use of antibiotics, among others [23–27].

2. Materials and methods

2.1. Study design

Randomized prospective, open-label, unblinded case-control controlled clinical trial with a control group that did not undergo the intervention. The study was approved in April 2020 by the Hospital Universitario de Torrevieja and Hospital Universitario del Vinalopó (Spain) Ethics Committee (approval protocol code: TV/VP-14042020). The study was registered at [Clinicaltrial.gov](https://www.clinicaltrials.gov) as NCT04390477.

2.2. Study population

Population included in the study were subjects admitted in the Internal Medicine Department or in the Home Hospitalized Unit of the Hospital Universitario del Vinalopó in Elche, Alicante (Spain). The inclusion criteria were patients over 18 years and SARS-CoV-2 diagnosis as per one positive oropharyngeal and nasopharyngeal COVID-19 swab. Prior to study inclusion, all patients were properly informed by the clinical trial investigators. Those who agreed, signed an informed consent to participate in the study.

During the study patients were allowed to receive COVID-19

therapeutic treatments, including hydroxychloroquine (200 mg twice a day for 7 days), azithromycin (500 mg once a day for 7 days), lopinavir–ritonavir (400/100 mg twice a day) or darunavir–cobicistat (800/150 mg once a day) for 14 days, and low molecular weight heparin for deep vein thrombosis prophylaxis, as recommended at the time by the Spanish Society of Infectious Diseases and the Hospital Infectious diseases Unit guidelines.

2.3. Randomizing and intervention

Patients were randomized in a ratio 5:3 to be assigned to 1 of the 2 trial arms using a computational randomization list. The intervention group received one nutraceutical probiotic supplement capsule a day for one month. Content per dose/capsule was *Lactobacillus rhamnosus* CECT 30579 1×10^9 CFU and *Kluyveromyces marxianus* B0399 with 1×10^8 CFU. The control group did not receive the intervention. Investigators received instructions on product storage, including keeping the product closed in a cool and dry place, and protected from direct sunlight.

The recommended daily dose is 1 oral capsule, which should preferably be taken with breakfast or other meal. In case of inability or issues to swallow the capsule, the content can be dissolved in little water and taken straightaway. The capsule contains the probiotic blend, calcium carbonate, gelatin (coating agent), maltodextrin (bulking agent) and magnesium stearate (anti-caking agent).

2.4. Outcome measurements

The study design includes two visits. In visit 1 patients were evaluated and those eligible according to protocol inclusion criteria were included in the study. After 30 days of the start of the study, visit 2 (end of the study) was carried out.

In visit 1 the clinical situation of the patients were evaluated measuring the parameters included in the protocol. Medical history was recorded together with the outcome of the examination results including all digestive symptoms as well as other signs and non-digestive symptoms, possible concomitant pathologies, habitual pharmacological treatments, blood tests, radiological evaluation, CURB-65 pneumonia severity score and description of symptoms related to COVID-19 infection. Besides, an antigen COVID-19 test was performed to every patient between 10 and 15 days from the onset of symptoms. In visit 2, in addition to the above-described evaluation, the following data was recorded: result of a second antigen test, the adherence to treatment and all adverse events occurred during the follow-up period.

The primary outcome was the total number of patients and percentage of those that showed improvement in digestive symptoms from baseline to final visit, comparing intervention group to control group. The secondary variables were: a) Total number of patients and percentage of those who improved in total symptoms; b) Total number of digestive symptoms and percentage of those that improved; c) Total number of total symptoms and percentage of those that improved; d) Number and percentage of cases discharged to the Intensive Care Unit (ICU); e) Number and percentage of cases that died; f) Number and percentage of patients who negativized the antigen test between day 10 and 15 from the onset of symptoms; and g) Number of adverse events attributable or not to the intervention product.

2.5. Statistical analysis and sample size calculation

The statistical analyses were conducted with Statistical Package for Social Science (SPSS) software, version 22 (IBM SPSS, Chicago, III). The analysis of the results has been carried out by protocol, that is, only those patients who completed the clinical study have been considered. During the statistical analysis we observed two types of variables, continuous and dichotomous. For the continuous variables, the Kolmogorov Smirnov

normality test was applied, from which it was observed that the distribution of these variables was normal in all cases. Therefore, the data was analyzed using Student's t-test and represented by the mean and standard deviation. The dichotomous variables were described as a frequencies and percentages (%), and then compared by the χ^2 test for the two groups. A two-sided p-value test of <0.05 was considered statistically significant.

To end, the sample size and the statistical power calculation were performed taking the total digestive symptoms variable as the basis for the calculation. When the study was designed, no published data could be found related to improvement of digestive symptoms in COVID-19 patients during the first month since diagnosis was done. Local experience from the Hospital where patients were recruited estimates a range between 25 and 45%. Taking the value 35% and expecting to detect in the intervention group a response of at least 80%, accepting an alpha risk of 0.05 and a beta risk of 0.2 in the 2-sided test and a drop out of 2%, 15 subjects are needed in the control group and 25 in the probiotic group for the difference to be statistically significant in proportion.

3. Results

From December 2020 to February 2021, forty-one patients with diagnosis of COVID-19 were enrolled in the study. The distribution of the sample remained with 26 patients in the probiotic group compared to 15 patients in the control group. Table 1 shows the general characteristics of the population included in the study, both demographic data and the variables associated with symptoms and signs related to COVID-19. There were no significant differences in the baseline characteristics between the 2 groups (Table 1). During the follow-up a total of 2 patients, both included in the probiotic group, decided to drop out once they were included in the study voluntarily. Missing data was not related to the treatment nor to the outcome. Only observed data was used in the analysis (Fig. 1).

Table 1
Demographic and Clinical Data Homogeneity Analysis. Comparison between groups at the baseline visit.

	Control (N = 15)	Probiotic (N = 26)	P value
Sex (Female), N (%)	10 (66.7%)	12 (46.1%)	0.21
Age (years), Mean \pm SD	46.33 \pm 10.91	48.88 \pm 12.35	0.51
Previous pathologies (HT, cardiovascular, diabetes, cancer, COPD), N (%)	3 (20%)	7 (26.9%)	0.62
Pharmacological treatments, N (%)	7 (46.7%)	14 (53.8%)	0.66
PCR diagnosis, N (%)	5 (33.3%)	8 (30.8%)	0.87
Antigen test diagnosis, N (%)	10 (66.7%)	18 (69.2%)	0.87
Hospital admission, N (%)	2 (13.3%)	9 (34.6%)	0.14
HHU admissions, N (%)	13 (86.7%)	17 (65.4%)	0.14
Fever, N (%)	12 (80%)	20 (76.9%)	0.82
Loss of sense of smell or taste, N (%)	6 (40%)	15 (57.7%)	0.28
Respiratory, N (%)	14 (93.3%)	23 (88.5%)	0.61
Dry cough, N (%)	13 (86.7%)	21 (80.8%)	0.63
Dyspnea, N (%)	1 (6.7%)	8 (30.8%)	0.07
Chest pain, N (%)	1 (6.67%)	6 (23.1%)	0.18
Sore throat, N (%)	6 (40%)	6 (23.1%)	0.26
Digestive, N (%)	15 (100%)	24 (92.3%)	0.27
Diarrhea, N (%)	12 (80%)	19 (73.1%)	0.62
Dyspepsia, N (%)	13 (86.7%)	10 (38.5%)	0.13
Heartburn, N (%)	2 (13.3%)	4 (15.4%)	0.86
Abdominal pain, N (%)	8 (53.3%)	9 (34.6%)	0.24
Nausea and/or vomiting, N (%)	12 (80%)	12 (46.1%)	0.15
Other symptoms, N (%)	15 (100%)	25 (96.1%)	0.44
Asthenia, N (%)	15 (100%)	24 (92.3%)	0.27
Musculoskeletal pain, N (%)	13 (86.7%)	21 (80.8%)	0.63
Conjunctivitis, N (%)	3 (20%)	4 (15.4%)	0.71
Headache, N (%)	13 (86.7%)	19 (73.1%)	0.31
Rash, N (%)	1 (6.7%)	0 (0%)	0.18
Total number of digestive symptoms, Mean \pm SD	3.13 \pm 0.99	2.08 \pm 1.23	0.07
Total number of signs and symptoms, Mean \pm SD	8.73 \pm 2.15	7.62 \pm 2.23	0.13
CURB-65 (Mild pneumonia, Groups 0 and 1), N (%)	15 (100%)	24 (92.3%)	0.55

HT: Hypertension. COPD: Chronic obstructive pulmonary disease. PCR: polymerase chain reaction. SD: Standard deviation. HHU: Home Hospitalization Unit. CURB 65: Pneumoniae Severity score (Confusion, Urea, Respiratory rate, Blood pressure, 65 years or older).

3.1. Main variable in the study

3.1.1. Patients with resolution of digestive symptoms

Table 2 shows the number of patients with digestive symptoms per group, as well as the number and percentage of patients with symptoms improvement between initial and final visit. There are significant differences when comparing pyrosis symptom mean data in both groups (placebo 33.3% vs probiotic 100%; p value = 0.05) and the abdominal pain symptom (placebo 62.5% vs probiotic 100%; p value = 0.04).

3.2. Secondary variables in the study

3.2.1. Patients with resolution of non-digestive symptoms

Results on the total number of patients and percentage of them grouped by symptoms are described in Table 3. At follow-up end, the number of patients presenting any symptom was 13/15 (92.8%) in the control group vs 14/24 (58.3%) in the probiotic one. The number of patients showing a completely resolution of symptoms comparing control group to probiotic group was 2/15 (13%) vs 10/24 (41.7%); p value = 0.06.

3.2.2. Evolution of digestive symptoms - total number and improvement of digestive symptoms

Table 4 shows data of the digestive symptoms and its improvement, featuring the mean of symptoms reported by each patient in both groups, given that only patients who had some gastrointestinal symptom in visit 1 were analyzed. Comparison between both groups show a nearly statistical significance difference (placebo 65% vs probiotic 87.95%; p value = 0.06).

3.2.3. Evolution of overall symptoms

Table 5 includes the mean of total symptoms per group, by averaging the rate of improvement in the overall symptom. Data shows statistical




Fig. 1. Consort diagram.

Table 2

Total number of patients and percentage of cases presenting improvement in digestive symptoms.

Symptoms	Group	Patients with symptoms in V1	Patients with symptoms in V2	Improve	P value
Digestive (N = 37)	Control	15	8	46.7%	0.11
	Probiotic	22	6	72.7%	
Diarrhea (N = 32)	Control	13	4	69.2%	0.31
	Probiotic	19	3	84.2%	
Dyspepsia (N = 23)	Control	13	3	76.9%	0.41
	Probiotic	10	1	90%	
Pyrosis (N = 7)	Control	3	2	33.3%	0.05*
	Probiotic	4	0	100%	
Abdominal pain (N = 17)	Control	8	3	62.5%	0.04*
	Probiotic	9	0	100%	
Nausea and/or vomiting (N = 23)	Control	12	4	66.7%	0.16
	Probiotic	11	1	90%	

V1: Visit 1. V2: Visit 2.

difference between groups with an improvement of 70.82% in the probiotic group vs 88.55% in the placebo group; p value = 0.027.

3.2.4. Other variables: number of patients discharged to ICU and number of patients who did during the follow up and number of patients which performed COVID-19 test in days 10–15

All patients included in the study were admitted in the Home Hospitalization Unit. The 39 analyzable patients were discharged home. No patient was discharged to the ICU nor died during the follow up.

To compare the possible effects of probiotic treatment on early negativization of the virus, between day 10 and 15 from the onset of symptoms, 24 of the 39 analyzable patients performed a rapid antigen test at home (the remaining 15 patients were not able to perform a rapid antigen test). One of them, included in the control group, was positive; the remaining 23 were negative.

3.2.5. Security analysis

All adverse events occurred during the follow-up period were collected by the investigators. A total of 11 patients reported adverse events during the study, 6 in the probiotic group and 5 in the control

Table 3

Total number of patients and percentage of cases presenting improvement of non-digestive symptoms.

Symptoms	Group	Patients with symptoms in V1	Patients with symptoms in V2	Improve	P value
Fever (N = 32)	Control	12	0	100%	–
	Probiotic	20	0	100%	
Anosmia/Ageusia (N = 20)	Control	6	2	66.7%	0.83
	Probiotic	14	4	71.4%	
Respiratory (N = 35)	Control	14	2	85.7%	0.32
	Probiotic	21	1	95.2%	
Dry cough (N = 32)	Control	13	2	84.6%	0.34
	Probiotic	19	1	94.7%	
Dyspnea (N = 8)	Control	1	0	100%	–
	Probiotic	7	0	100%	
Chest pain (N = 6)	Control	1	0	100%	–
	Probiotic	5	0	100%	
Throat pain (N = 12)	Control	6	1	83.3%	0.30
	Probiotic	6	0	100%	
Asthenia (N = 37)	Control	15	8	46.7%	0.64
	Probiotic	22	10	54.5%	
Musculoskeletal pain (N = 32)	Control	13	4	69.2%	0.01*
	Probiotic	19	0	100%	
Conjunctivitis (N = 7)	Control	3	0	100%	–
	Probiotic	4	0	100%	
Headache (N = 31)	Control	13	2	84.6%	0.09
	Probiotic	18	0	100%	
Rashes (N = 1)	Control	1	0	100%	–
	Probiotic	0	0	–	0.34

V1: Visit 1. V2: Visit 2.

Table 4

Total number and improvement of digestive symptoms.

Digestive symptoms	Control (N = 15)	Probiotic (N = 22)	P value
Total number V1, Mean	3.13	2.36	
Total number V2, Mean	1.13	0.32	
Improvement index V1–V2, % Mean ± SD	65% ± 39.86	87.95% ± 24.26	0.06

V1: Visit 1. V2: Visit 2. SD: Standard deviation.

Table 5
Total number and improvement of overall symptoms.

Overall symptoms	Control (N = 15)	Probiotic (N = 24)	P value
Total number V1, Mean	8.73	7.71	
Total number V2, Mean	2.47	0.92	
Improvement index V1–V2, % Mean ± SD	70.82% ± 26.48	88.55% ± 13.85	0.03*

V1: Visit 1. V2: Visit 2. SD: Standard deviation.

Table 6
Description of patients and adverse events in both follow-up groups.

Control	Probiotic
Renal colic	Nausea and increased frequency of bowel movements
Low back pain	Mild constipation and Poor digestion - bloating
Weight loss; 6 kg	Mild constipation
Persistent fatigue and dyspnea	Renal colic and DVT
Persistent dyspnea	Mild intermittent swelling Headaches/dizziness

DVT: Deep Vein Thrombosis.

group (Table 6). Bearing in mind that only the patients in the probiotic group received treatment and analysing the possible side effects of the product under study, we emphasize that none of the 7 described adverse events were considered potentially attributable to the product under study.

4. Discussion

As previously mentioned, few studies have evaluated the efficacy of certain probiotic strains as an option to improve moderated COVID-19 recovery rates in adults; however, to date, there is no strong experimental evidence supporting their effectiveness and safety in real clinical practice. Importantly, evidence and clinical trials demonstrating strain-specific effects are lacking. The clinical trial reported herein explores the role of a mixture of probiotics administered to patients with moderate COVID-19. Several variables, such as treatments used for COVID-19 besides other concomitant diseases were controlled to avoid bias. Our results suggest that administration of the probiotic mixture under study (yeast strain *Kluyveromyces marxianus* B0399 plus *Lactobacillus rhamnosus* CECT 30579), as adjuvant treatment, can be effective in reducing the symptoms and thus, shortening the time needed for full recovery in symptomatic patients with an acute episode of COVID-19. The response rate of patients was statistically significant higher in the probiotic group comparing to the no intervention group when analyzed the symptoms pyrosis, abdominal pain and the overall symptoms.

The clinical response observed in the main variable “Patients with resolution on digestive symptoms” was in the same line as observed in other previous clinical controlled studies testing probiotics on COVID-19 [21]. 72.7% of patients remained free of digestive symptoms at the end of the first month follow-up in the probiotic group in our study. Data from the Gutierrez-Castrellon et al. study showed 53% of response in the same variable and same follow up period.

Moreover, despite the low number of patients in our study, the magnitude of the difference in the number of patients showing a completely resolution of symptoms comparing control and probiotic group reaches almost significant statistical difference (13% vs 41.7%; p value = 0.06). Several factors which may influence the response to probiotic treatment on COVID-19 were considered when the protocol of this clinical study was designed: older patients have more dysbiosis than young ones, besides some different treatments prescribed to COVID-19 patients such as antibiotics, can affect the microbiota composition and

hence the rates of response to probiotic treatment [28,29]. Interestingly not only digestive symptoms improved when the probiotic was administered. The osteo-muscular pain and the overall symptoms also improved in the probiotic group when compared to the non-interventional group. This effect suggests a systemic effect of probiotic on the immunomodulatory and inflammatory systemic biomarkers, as proposed in other inflammatory, infectious and immunity systemic diseases [30]. Decreased activity of the T helper 2 cells, lipopolysaccharides and viral DNA in the peripheral blood of patients included in the probiotic arm as a consequence of the use of probiotic has been described [31].

The final blend used in the study included *Kluyveromyces marxianus fragilis* B0399, the first non-Saccharomyces yeast approved as a probiotic for human consumption [23]. This strain has demonstrated to be effective in the recovery of digestive symptoms, besides a potential in some other diseases such as intestinal bowel diseases, halitosis, lactic intolerance, and antibiotic side effects. In patients with IBS (Intestine Bowel Syndrome) administration of a fermented milk containing *Kluyveromyces marxianus fragilis* B0399 and other probiotic species, improved symptoms [27]. In subjects with halitosis, which the cause is probably due to bacterial disbalance, the administration of *Kluyveromyces marxianus* B0399 capsules for two weeks allowed to eliminate halitosis in 91% of patients. Mechanism of action of probiotic was the restoration of the gut microbiota, not acting at the oral level [26].

The other strain in this mixture is *Lactobacillus rhamnosus* CECT 30579 that has been proved in a mixture for digestive symptoms with good results and effectiveness (internal data unpublished). It is interesting to note that none of the previously published clinical trials in COVID-19 patients evaluate the effect of a yeast in the evolution of these patients. Only one study evaluates the effect of a Nutritional Support System administered orally and intramuscularly. This treatment includes some different compounds and vitamins, including the probiotic yeast *Saccharomyces boulardii* but administered orally only during the first 6 days of intervention [22]. *Kluyveromyces marxianus* B0399 is especially interesting because it is a proven strain not only in the treatment of digestive symptoms but also with immunomodulatory potential [32]. Another factor in favor of its selection is that both strains have been previously used in elderly and immunocompromised patients without significant side effects and with very good tolerance by patients [23,26,27].

Limitations to the study should be considered, including among others the low number of patients evaluated and the non-blinded open label clinical trial due to the fact that the study design was performed during the first COVID-19 pandemic wave when researchers had important restrictions to access to patients, as well as the fact that non usual practices were not allowed, and this is why no samples of stool for microbiota study were collected. Besides, the time of intervention and to know if longer treatment could benefit a greater number of patients, are another unresolved questions. Applicability of our results and whether they can be extended to other populations such as patients with severe COVID-19 are points to solve and clarified through further research.

5. Conclusions

The results of our study indicate a positive effect in reducing the total number of digestive symptoms and overall symptoms in the group treated with the probiotic mixture. This evidence supports the efficacy of administering this probiotic mixture to patients with moderate COVID-19 and suggests that it could be an effective coadjuvant treatment that could be used more extensively in clinical practice.

Author contributions

Conceptualization, V.N.-L., A.H.-B. and M.I.P.-S.; Formal analysis, J.A.-S., D.P.-M. and L.N. M.; Methodology, V.N.-L., M.A.-G and D.P.-M.; Software, L.N.-M.; Validation, M.I.P.-S., M.A.-G., G.L.-R., E.R.-S., M.M.-

G., P.S.-P., E.N.-D., B.R.-C. and J.A.P.-M.; Writing—original draft preparation, V.N.-L. and J.A.-S.; Writing—review and editing, A.H.-B., M.I.P.-S., M.A.-G., G.L.-R., E.R.-S., M.M. G., P.S.-P., E.N.-D., B.R.-C., J.A.P.-M. and D.P.-M.; Supervision, J.A.-S. and B.R.-C.; Project administration, V.N. L.

Conflicts of interest

A.H.-B., M.I.P.-S., M.A.-G., G.L.-R., E.R.-S., M.M.-G., D.P.-M. and J.A.P.-M declare no conflicts of interests. V.N.-L is the Research Director of Bioithas, S.L. P.S.-P., J.A.-S., E.N.-D., B.R. C. and L.N.-M. are employees of Bioithas, S.L.

Acknowledgments

This research was promoted by Bioithas, S.L. and partially funded by an award of the Instituto Valenciano de Competitividad Empresarial, Comunidad Valenciana, Spain (Proyectos de I + D (PIDI-CV); Grant number: IMIDTA/2021/107).

References

- Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (COVID-19). medRxiv 2020. <https://doi.org/10.1101/2020.02.14.20023127>.
- Foladori P, Cutrupi F, Segata N, Manara S, Pinto F, Malpei F, Bruni L, La Rosa G. SARS-CoV-2 from faeces to wastewater treatment: what do we know? A review. *Sci Total Environ* 2020;743:140444. <https://doi.org/10.1016/j.scitotenv.2020.140444>.
- Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol* 2020;251:228–48. <https://doi.org/10.1002/path.5471>.
- Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med* 2020;26:502–5. <https://doi.org/10.1038/s41591-020-0817-4>.
- Willers M, Viemann D. Role of the gut microbiota in airway immunity and host defense against respiratory infections. *Biol Chem* 2021;402:1481–91. <https://doi.org/10.1515/hsz-2021-0281>.
- Liu Y, Kuang D, Li D, Yang J, Yan J, Xia Y, Zhang F, Cao H. Roles of the gut microbiota in severe SARS-CoV-2 infection. *Cytokine Growth Factor Rev* 2022;63: 98–107. <https://doi.org/10.1016/j.cytogfr.2022.01.007>.
- Ezechukwu HC, Diya CA, Eogh LJ, Abiodun MJ, Grace JA, Okoh GR, Adu KT, Adegboye OA. Lung microbiota dysbiosis and the implications of SARS-CoV-2 infection in pregnancy. *Ther Adv Infect Dis* 2021;8:20499361211032453. <https://doi.org/10.1177/20499361211032453>.
- Wang H, Wang H, Sun Y, Ren Z, Zhu W, Li A, Cui G. Potential associations between microbiome and COVID-19. *Front Med* 2021;8:785496. <https://doi.org/10.3389/fmed.2021.785496>.
- Page MJ, Kell DB, Pretorius E. The role of lipopolysaccharide-induced cell signalling in chronic inflammation. *Chronic Stress (Thousand Oaks)* 2022;6: 24705470221076390. <https://doi.org/10.1177/24705470221076390>.
- Cardinale V, Capurso G, Ianiro G, Gasbarrini A, Arcidiacono PG, Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. *Dig Liver Dis* 2020;52:1383–9. <https://doi.org/10.1016/j.dld.2020.09.009>.
- Li XY, He C, Zhu Y, Lu NH. Role of gut microbiota on intestinal barrier function in acute pancreatitis. *World J Gastroenterol* 2020;26:2187–93. <https://doi.org/10.3748/wjg.v26.i18.2187>.
- Singh DD, Sharma A, Lee HJ, Yadav DK. SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy. *Front Cell Infect Microbiol* 2022;12:839170. <https://doi.org/10.3389/fcimb.2022.839170>.
- Kirtipal N, Kumar S, Dubey SK, Dwivedi VD, Gireesh Babu K, Maly P, Bharadwaj S. Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. *Infect Genet Evol* 2022;99:105254. <https://doi.org/10.1016/j.meegid.2022.105254>.
- Labandeira-Garcia JL, Labandeira CM, Valenzuela R, Pedrosa MA, Quijano A, Rodriguez-Perez AI. Drugs modulating renin-angiotensin system in COVID-19 treatment. *Biomedicines* 2022;10. <https://doi.org/10.3390/biomedicines10020502>.
- Theodorakopoulou MP, Alexandrou ME, Boutou AK, Ferro CJ, Ortiz A, Sarafidis P. Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. *Clin Kidney J* 2022;15: 397–406. <https://doi.org/10.1093/ckj/sfab272>.
- Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. *Antonie Leeuwenhoek* 2020;113:2019–40. <https://doi.org/10.1007/s10482-020-01474-7>.
- Kim SK, Guevarra RB, Kim YT, Kwon J, Kim H, Cho JH, Kim HB, Lee JH. Role of probiotics in human gut microbiome-associated diseases. *J Microbiol Biotechnol* 2019;29:1335–40. <https://doi.org/10.4014/jmb.1906.06064>.
- Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* 2019;16:605–16. <https://doi.org/10.1038/s41575-019-0173-3>.
- Meng X, Zhang G, Cao H, Yu D, Fang X, de Vos WM, Wu H. Gut dysbiosis and intestinal disease: mechanism and treatment. *J Appl Microbiol* 2020;129:787–805. <https://doi.org/10.1111/jam.14661>.
- Rodriguez JAM, Bifano M, Roca Goma E, Plasencia CM, Torralba AO, Font MS, Millan PR. Effect and tolerability of a nutritional supplement based on a synergistic combination of beta-glucans and selenium- and zinc-enriched *Saccharomyces cerevisiae* (ABB C1((R))) in volunteers receiving the influenza or the COVID-19 vaccine: a randomized, double-blind, placebo-controlled study. *Nutrients* 2021;13. <https://doi.org/10.3390/nu13124347>.
- Gutierrez-Castrellon P, Gandara-Marti T, Abreu YAAT, Nieto-Rufino CD, Lopez-Orduna E, Jimenez-Escobar I, Jimenez-Gutierrez C, Lopez-Velazquez G, Espadaler-Mazo J. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. *Gut Microb* 2022;14:2018899. <https://doi.org/10.1080/19490976.2021.2018899>.
- Leal-Martinez F, Abarca-Bernal L, Garcia-Perez A, Gonzalez-Tolosa D, Cruz-Cazares G, Montell-Garcia M, Ibarra A. Effect of a nutritional support system to increase survival and reduce mortality in patients with COVID-19 in stage III and comorbidities: a blinded randomized controlled clinical trial. *Int J Environ Res Publ Health* 2022;19. <https://doi.org/10.3390/ijerph19031172>.
- Quarella S, Lovrovich P, Scalabrini S, Campedelli I, Backovic A, Gatto V, Cattonaro F, Turello A, Torriani S, Felis GE. Draft genome sequence of the probiotic yeast *Kluyveromyces marxianus fragilis* B0399. *Genome Announc* 2016;4. <https://doi.org/10.1128/genomeA.00923-16>.
- Maccaferri S, Candela M, Turrioni S, Centanni M, Severgnini M, Consolandi C, Cavina P, Brigidi P. IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation. *Gut Microb* 2012;3: 406–13. <https://doi.org/10.4161/gmic.21009>.
- Fonseca GG, Heinze E, Wittmann C, Gombert AK. The yeast *Kluyveromyces marxianus* and its biotechnological potential. *Appl Microbiol Biotechnol* 2008;79: 339–54. <https://doi.org/10.1007/s00253-008-1458-6>.
- Cecchini FN, Zanvit A, Miclavet A, Nobili P. Halitosis treatment through the administration of antibiotic-resistant probiotic lactic yeast *Kluyveromyces marxianus fragilis* B0399 (K-B0399). *A. Biomed J Scient Tech Res* 2018;12: 8887–90.
- Lisotti AE, Mazzella G. Su2037 effects of a fermented milk containing *Kluyveromyces marxianus* B0399 and *Bifidobacterium Lactis* BB12 in patients with irritable bowel syndrome: a new effective agent. *R. Gastroenterology* 2013;144: 538–9.
- Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. *Trends Mol Med* 2016;22:458–78. <https://doi.org/10.1016/j.molmed.2016.04.003>.
- Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. *Microbiology (Read)* 2010;156: 3216–23. <https://doi.org/10.1099/mic.0.040618-0>.
- Cristofori F, Dargenio VN, Dargenio A, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. *Front Immunol* 2021;12:578386. <https://doi.org/10.3389/fimmu.2021.578386>.
- Zhang CX, Wang HY, Chen TX. Interactions between intestinal microflora/probiotics and the immune system. *BioMed Res Int* 2019;2019:6764919. <https://doi.org/10.1155/2019/6764919>.
- Maccaferri S, Klinder A, Brigidi P, Cavina P, Costabile A. Potential probiotic *Kluyveromyces marxianus* B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system. *Appl Environ Microbiol* 2012;78:956–64. <https://doi.org/10.1128/AEM.06385-11>.